Pediatrix Medical Group (MD) Projected to Announce Earnings on Thursday

Key Points

• Pediatrix Medical Group is expected to report Q3 2026 results before the market opens on October 29. Analysts forecast earnings of $0.65 per share on revenue of $498.18 million.
• The company’s latest quarter exceeded expectations, with EPS of $0.63 versus the $0.59 consensus and revenue of $487.78 million, up 4.1% year over year.
• MD shares opened at $28.07, near their 52-week high of $28.29. Wall Street maintains a consensus “Hold” rating, with an average price target of $26.60.

Pediatrix Medical Group (NYSE:MD - Get Free Report) will likely be releasing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of $0.65 per share and revenue of $498.18 million for the quarter. Investors may visit the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 9:00 AM ET.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.04. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The firm had revenue of $487.78 million for the quarter, compared to analyst estimates of $478.49 million. During the same quarter in the prior year, the firm earned $0.53 EPS. The business's revenue for the quarter was up 4.1% compared to the same quarter last year. On average, analysts expect Pediatrix Medical Group to post $2.17 EPS for the current fiscal year and $2.23 EPS for the next fiscal year.

Pediatrix Medical Group Stock Performance

NYSE MD opened at $28.07 on Thursday. Pediatrix Medical Group has a 52-week low of $16.82 and a 52-week high of $28.29. The company has a fifty day moving average of $26.55 and a 200-day moving average of $24.86. The company has a market capitalization of $2.28 billion, a P/E ratio of 13.43 and a beta of 0.61. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.32.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MD. Wall Street Zen raised Pediatrix Medical Group from a "buy" rating to a "strong-buy" rating in a research note on Sunday, September 13th. Truist Financial upped their price objective on Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a "hold" rating in a report on Tuesday, July 14th. Jefferies Financial Group lowered Pediatrix Medical Group from a "buy" rating to a "hold" rating and increased their price objective for the company from $27.00 to $28.00 in a research report on Wednesday, August 19th. UBS Group increased their price objective on Pediatrix Medical Group from $25.00 to $28.00 and gave the company a "neutral" rating in a research report on Thursday, August 6th. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a $25.00 price objective on shares of Pediatrix Medical Group in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $26.60.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc provides specialized physician-led healthcare services for women, infants and children. The company's clinical offerings include neonatal and perinatal care, maternal-fetal medicine, pediatric medical subspecialties, pediatric hospitalist services and related services delivered in partnership with hospitals and healthcare systems.

Pediatrix-affiliated physicians and advanced practice providers generally work in hospital-based settings, including neonatal intensive care units, delivery rooms, pediatric units and outpatient practices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.